Catalent Inc (NASDAQ:CTLT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, April 20th. The brokerage presently has a $31.00 target price on the stock. Zacks Investment Research‘s target price points to a potential downside of 8.34% from the stock’s current price.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other research analysts have also issued research reports about the stock. TheStreet raised shares of Catalent from a “d+” rating to a “c” rating in a research note on Monday, February 6th. Jefferies Group LLC increased their target price on shares of Catalent from $29.00 to $32.00 and gave the stock a “hold” rating in a research note on Monday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $30.71.
Catalent (NASDAQ:CTLT) opened at 33.82 on Thursday. Catalent has a 52 week low of $20.94 and a 52 week high of $34.81. The stock has a 50 day moving average price of $29.80 and a 200-day moving average price of $27.52. The stock has a market cap of $4.23 billion and a P/E ratio of 39.84.
Catalent (NASDAQ:CTLT) last announced its earnings results on Thursday, May 4th. The company reported $0.38 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.02. The company had revenue of $532.60 million for the quarter, compared to analysts’ expectations of $470.95 million. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period last year, the business earned $0.21 EPS. On average, equities analysts anticipate that Catalent will post $1.38 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Catalent Inc (CTLT) Lifted to “Buy” at Zacks Investment Research” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/05/20/catalent-inc-ctlt-stock-rating-upgraded-by-zacks-investment-research-updated-updated-updated.html.
In other news, insider John R. Chiminski sold 73,819 shares of the firm’s stock in a transaction that occurred on Monday, March 20th. The shares were sold at an average price of $28.62, for a total value of $2,112,699.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sharon Johnson sold 9,160 shares of the firm’s stock in a transaction that occurred on Tuesday, April 25th. The shares were sold at an average price of $29.00, for a total transaction of $265,640.00. The disclosure for this sale can be found here.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its position in Catalent by 5.8% in the first quarter. Goldman Sachs Group Inc. now owns 2,884,504 shares of the company’s stock valued at $81,690,000 after buying an additional 159,081 shares during the last quarter. Macquarie Group Ltd. raised its position in Catalent by 15.5% in the first quarter. Macquarie Group Ltd. now owns 1,115,335 shares of the company’s stock valued at $31,586,000 after buying an additional 149,564 shares during the last quarter. Gareth Morgan Investments Limited Partnership acquired a new position in Catalent during the first quarter valued at approximately $1,925,000. Tudor Investment Corp ET AL raised its position in Catalent by 29.8% in the first quarter. Tudor Investment Corp ET AL now owns 17,521 shares of the company’s stock valued at $496,000 after buying an additional 4,021 shares during the last quarter. Finally, Redmile Group LLC acquired a new position in Catalent during the first quarter valued at approximately $17,672,000.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.